AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19587364
Drug: Male sex
RxNorm normalized name: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Male sex and insulin sensitivity
Trial: 8934214
Drug: Nitrendipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (5 mg bid)
Trial: 6416701
Drug: 30 mg/30
RxNorm normalized name: Kapectolin, 5.8 g-130 mg/30 mL oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/30 ml Adriamycin
Trial: 6416701
Drug: 20 mg/40
RxNorm normalized name: mitomycin 20 mg/40 mL (0.5 mg/mL) INTRAVESIC SYRINGE (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/40 ml Adriamycin
Trial: 6416701
Drug: 20 mg/40
RxNorm normalized name: mitomycin 20 mg/40 mL (0.5 mg/mL) INTRAVESIC SYRINGE (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/40 ml mitomycin C
Trial: 27379829
Drug: Daily combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily combination of vitamin D3 (1200 IU), folic acid (0.5 mg), vitamin B12 (0.5 mg), vitamin B6 (50 mg), and calcium carbonate (456 mg) (group A)
Trial: 22217987
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg orally daily for 4 days, then 200 mg once weekly for 6 months
Trial: 22217987
Drug: K-712, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-712, 1 tablet twice a day for 4 weeks and then for the first 2 weeks of each month for a total of 6 months
Trial: 17323595
Drug: Sildenafil (phosphodiesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (phosphodiesterase type 5 inhibitor)
Trial: 15206088
Drug: Ointment-based product
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment-based product
Trial: 15206088
Drug: Aerosol spray
RxNorm normalized name: Betadine Aerosol Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol spray
Trial: 11148806
Drug: Low-dose sequential
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sequential HRT
Trial: 9102063
Drug: MFP-SR (76
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFP-SR (76 mg b.i.d.)
Trial: 26650434
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (2.2 g protein/kg/day)
Trial: 26650434
Drug: Standard-protein diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-protein diet (1.1 g protein/kg/day)
Trial: 25899445
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg weekly dose of sirolimus (SIR)
Trial: 23537892
Drug: Intravenous B-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous B-type natriuretic peptide (BNP)
Trial: 12690275
Drug: GenHevac B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GenHevac B vaccine (3 standard injections at 30-day intervals)
Trial: 12690275
Drug: GenHevac B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GenHevac B vaccine
Trial: 12579420
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 15 ml/kg
Trial: 12579420
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 5 ml/kg after volume resuscitation
Trial: 12579420
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 10 ml/kg after volume resuscitation
Trial: 12579420
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 15 ml/kg after volume resuscitation
Trial: 1820897
Drug: 5‐ASA capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA capsule formulation
Trial: 1820897
Drug: Single unit
RxNorm normalized name: LIDOCAINE 4 g TOPICAL PATCH [LIDOCORE (single unit patch)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single unit tablet of 5‐ASA
Trial: 6349765
Drug: Bacille Calmette-Guérin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacille Calmette-Guérin (BCG) maintenance therapy
Trial: 6349765
Drug: Cyclophosphamide (orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (orally administered)
Trial: 26951205
Drug: Phenolic-rich olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenolic-rich olive leaf extract (OLE) 136 mg oleuropein; 6 mg hydroxytyrosol
Trial: 26774673
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) supplementation (2 × 500 mg/day for four months)
Trial: 15786549
Drug: 3-day rabeprazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day rabeprazole-based triple therapy (amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., rabeprazole 20 mg b.i.d.)
Trial: 15786549
Drug: 7-day rabeprazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day rabeprazole-based triple therapy (amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., rabeprazole 20 mg b.i.d.)
Trial: 15786549
Drug: 3-day rabeprazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day rabeprazole-based triple therapy
Trial: 11932292
Drug: fenproporex 25
RxNorm normalized name: fenproporex 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenproporex 25 mg/d
Trial: 11932292
Drug: sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sibutramine 10 mg/d
Trial: 11932292
Drug: orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orlistat 120 mg tid
Trial: 9428449
Drug: Bicarbonate bath
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate bath of 40 mEq/L (experimental group)
Trial: 9428449
Drug: Standard bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bicarbonate bath of 35 mEq/L (control group)
Trial: 8085374
Drug: SPf(66)n, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf(66)n, a chimeric molecule derived from Plasmodium falciparum proteins, details on dosage and duration not available
Trial: 1008247
Drug: Modification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modification of infusion regimen (substituting glucose solution with distilled water and Ringer lactate with normal saline and 5 mval/l KCI)
Trial: 30484833
Drug: Any oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any oral anticoagulant
Trial: 26817808
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy and general discussions (Group C)
Trial: 20194455
Drug: Nonbiologic DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonbiologic DMARD treatment after 12 weeks
Trial: 20194455
Drug: Low response
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low response to treatment at 12 weeks
Trial: 14668283
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid + Iron (60 mg)
Trial: 14668283
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid + Iron + Zinc (30 mg)
Trial: 11289091
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with morphine and ketorolac
Trial: 9428033
Drug: Nucleus Mini
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleus Mini 22 Cochlear Implant System with SPEAK coding strategy
Trial: 9428033
Drug: Clarion Cochlear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarion Cochlear Implant System with CIS coding strategy (and one with CA coding strategy)
Trial: 9428033
Drug: Nucleus Mini
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleus Mini 22 Cochlear Implant System
Trial: 9428033
Drug: Clarion Cochlear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarion Cochlear Implant System
Trial: 10133873
Drug: Peripheral parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral parenteral nutrition
Trial: 2516090
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose administration (D5W)
Trial: 30701617
Drug: Continuous moderate‐intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous moderate‐intensity exercise + prior carbohydrate intake (10 g per person)
Trial: 26124907
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg OD for 12 weeks)
Trial: 26124907
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg OD for 12 weeks)
Trial: 26124907
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg OD) + Atorvastatin (10 mg OD for 12 weeks)
Trial: 26124907
Drug: Control (No
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (No treatment)
Trial: 23872701
Drug: Low-dose interoceptive
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose interoceptive exposure (IE) as prescribed in Panic Control Treatment
Trial: 23872701
Drug: Low-dose interoceptive
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose interoceptive exposure (IE) without controlled breathing
Trial: 19843741
Drug: Oral contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contrast media
Trial: 19843741
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and IV contrast media
Trial: 19843741
Drug: Simulated low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated low radiation dose
Trial: 17402790
Drug: Bispecific antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific antibodies
Trial: 17402790
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antibodies
Trial: 17402790
Drug: VEGF or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF or VEGF receptor blockers
Trial: 17402790
Drug: Heat shock
RxNorm normalized name: Human heat shock protein antigen 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat shock protein 90 inhibitors
Trial: 17402790
Drug: Multi-targeted kinase
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-targeted kinase inhibitors (sunitinib, sortenib)
Trial: 12888156
Drug: No anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anthracycline treatment
Trial: 10579147
Drug: Celgene formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celgene formulations (two formulations)
Trial: 10579147
Drug: Tortuga formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tortuga formulation
Trial: 10579147
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three formulations
Trial: 1680649
Drug: 19.2 mg
RxNorm normalized name: ALUMINUM SESQUICHLOROHYDRATE 19.2 mg in 100 g TOPICAL AEROSOL, SPRAY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19.2 mg oral dose of [14C]PV
Trial: 1680649
Drug: 9.9 mg
RxNorm normalized name: benzocaine 9.9 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.9 mg iv dose of [14C]PV
Trial: 1680649
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg nonradiolabeled oral dose of PV
Trial: 6802413
Drug: Desferrioxamine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (average weekly doses of more than 4 g)
Trial: 31843024
Drug: Amiloride 10
RxNorm normalized name: amiloride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 10 mg/day
Trial: 31843024
Drug: Amiloride 20
RxNorm normalized name: amiloride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 20 mg/day
Trial: 25367904
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600 mg every 12 hours
Trial: 21707862
Drug: Pet therapy
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pet therapy intervention for 6 weeks
Trial: 21707862
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pet therapy)
Trial: 19779146
Drug: Serotonin and
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin and noradrenaline selective reuptake inhibitor (SNRI)
Trial: 17005087
Drug: Simotang oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simotang oral liquid
Trial: 10731485
Drug: Arbutamine infusion
RxNorm normalized name: ARBUTAMINE
DrugBank: Arbutamine (DB01102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arbutamine infusion
Trial: 6241563
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g tiapride daily for 3 weeks
Trial: 30857452
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy for fast ventricular arrhythmia (VA)
Trial: 30857452
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy for slow VA
Trial: 29356759
Drug: Modified primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified primary continuous prophylaxis started by 25 IU/kg once per week, increased to twice or 3 times a week according to defined bleeding events.
Trial: 23848944
Drug: Internet-based problem-solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based problem-solving therapy (PST)
Trial: 16752268
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral micronized 17beta‐estradiol
Trial: 8406348
Drug: Two 5‐micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 5‐micrograms doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 month (group 1)
Trial: 8406348
Drug: Three 5‐micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 5‐micrograms doses of hepatitis B recombinant DNA yeast vaccine at 0, 1 and 6 months (group 2)
Trial: 8406348
Drug: Three 10‐micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 10‐micrograms doses of plasma‐derived hepatitis B vaccine (group 3)
Trial: 2869540
Drug: Temazepam 40
RxNorm normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Temazepam 40 mg orally followed by IV saline
Trial: 2869540
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo followed by IV diazepam 10 mg (Diazemuls)
Trial: 27645620
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of ofatumumab combined with bendamustine or fludarabine and cyclophosphamide chemotherapy
Trial: 27645620
Drug: Mega dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mega dose of ofatumumab combined with bendamustine or fludarabine and cyclophosphamide chemotherapy
Trial: 22799111
Drug: Glimepiride 1/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1/2 mg
Trial: 18266669
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion at 5 microg/min
Trial: 18266669
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion at 10 microg/min
Trial: 18266669
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion at 15 microg/min
Trial: 18266669
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion at 20 microg/min
Trial: 15715892
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg twice a day for 2 months
Trial: 11302252
Drug: BCNU 150
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCNU 150 mg/m2/i.v. followed by temozolomide 550 mg/m2/p.o. (Arm A)
Trial: 11302252
Drug: BCNU 100
RxNorm normalized name: BCNU 100 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCNU 100 mg/m2/i.v. followed by temozolomide 400 mg/m2/p.o. (Arm B)
Trial: 11302252
Drug: Temozolomide pharmacokinetics
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide pharmacokinetics
Trial: 8135447
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (100 mg of recombinant tissue plasminogen activator)
Trial: 2811366
Drug: Aminoglutethimide treatment
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide treatment (250 mg q.i.d. with hydrocortisone 50 mg b.i.d. for 2 weeks, then 25 mg b.i.d.)
Trial: 23618477
Drug: L-carnosine (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnosine (1500 mg)
Trial: 20691839
Drug: Primary PCI
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary PCI with adjunctive enoxaparin and abciximab
Trial: 18257780
Drug: Nateglinide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (120 mg before each main meal)
Trial: 9376455
Drug: Drug-free (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free (after haloperidol)
Trial: 1587076
Drug: Stopping medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping medication under open-label conditions (weeks 190 to 210)
Trial: 1587076
Drug: Transfer from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer from fenfluramine plus phentermine to no medication
Trial: 26072017
Drug: M72/AS01E vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M72/AS01E vaccine
Trial: 24607029
Drug: CRT-D treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-D treatment
Trial: 24607029
Drug: CRT-D treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-D treatment with left bundle branch block (LBBB)
Trial: 17631314
Drug: Aripiprazole 20
RxNorm normalized name: aripiprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 20 mg/day
Trial: 6342332
Drug: Ibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 800 mg X 3 daily
Trial: 18628266
Drug: Topical conjunctival
RxNorm normalized name: Sus scrofa conjunctiva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical conjunctival anaesthesia with a 1:1 mixture of lidocaine 2% and levobupivacaine 0.75%
Trial: 1963015
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg/day (4000 anti-Factor Xa IU), administered in one or two subcutaneous injections
Trial: 1963015
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg/day (one or two injections daily)
Trial: 1963015
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg/day, begun 12 h pre-operatively
Trial: 380804
Drug: Levamisole, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole, 150 mg/day orally for 3 consecutive days every other week
Trial: 29735587
Drug: Low-dose pitavastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pitavastatin (1 mg/d)
Trial: 28570161
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg daily (n=9)
Trial: 23561330
Drug: Low-dose β‐conglycinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose β‐conglycinin (2.3 g/d)
Trial: 23561330
Drug: High-dose β‐conglycinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose β‐conglycinin (4.6 g/d)
Trial: 23561330
Drug: Placebo (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (four casein tablets/d)
Trial: 22717090
Drug: Risperidone with
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone with light therapy
Trial: 18235414
Drug: Anti-angiogenesis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-angiogenesis treatment (humanized monoclonal antibody targeting vascular endothelial growth factor)
Trial: 18235414
Drug: Anti-angiogenesis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-angiogenesis treatment (low-molecular-weight anti tyrosine kinases)
Trial: 11136285
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid alone (10 mg.day/kg)